

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived human BMP-4 protein Ser293-Arg408 Accession # Q53XC5
N-terminal Sequence Analysis	Ser293
Structure / Form	Disulfide-linked homodimer
Predicted Molecular Mass	13 kDa (monomer)



SPECIFICATIONS

SDS-PAGE	22-25 kDa, reducing conditions 37-41 kDa, non-reducing conditions
Activity	Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells. Binnerts, M.E. <i>et al.</i> (2004) <i>Biochem. Biophys. Res. Commun.</i> 315(2) :272. The ED ₅₀ for this effect is typically 2.5-15 ng/mL.
Endotoxin Level	<0.01 EU per 1 µg of the protein by the LAL method.
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Formulation	Lyophilized from a 0.2 µm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 50-200 µg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 3 months, -70 °C under sterile conditions after reconstitution.

DATA

<p>Bioactivity</p>  <p>Recombinant Human BMP-4 (Catalog # 314-BP/CF) induces alkaline phosphatase production in the ATDC5 mouse chondrogenic cell line. The ED₅₀ for this effect is 2.5-15 ng/mL.</p>	<p>SDS-PAGE</p>  <p>1 µg/lane of Recombinant Human BMP-4 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing major bands at 22-25 kDa and 37-41 kDa, respectively. Multiple bands in gel are due to variable glycosylation.</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BACKGROUND

BMP-4 is a TGF- β superfamily ligand that is widely expressed from early embryogenesis through adulthood. It plays an important role in mesenchyme formation, epidermal determination, suppression of neural induction, the development of multiple organs, and tissue repair (1-5). The human BMP-4 precursor contains a 273 amino acid (aa) propeptide and a 116 aa mature protein (6). Processing of the propeptide by furin or proprotein convertase 6 enables the formation of the mature disulfide-linked homodimeric BMP-4 and facilitates its secretion. Similar intracellular processes may lead to the formation and recreation of BMP4/BMP7 disulfide-linked heterodimer (7-9). Mature human and mouse BMP-4 share 98% aa sequence identity. Human BMP-4 shares 85% aa sequence identity with human BMP-2 and less than 50% with other human BMPs. Compared to BMP-4 homodimers, BMP-4/BMP-7 heterodimers exhibit a greater potency in inducing osteogenic differentiation (9). In *Xenopus*, the heterodimers can also induce the formation of mesoderm, whereas BMP-4 homodimers only provide ventralizing signals for existing mesoderm (10). BMP-4 signals through tetrameric complexes composed of type I (primarily Activin RIA or BMPR-IA) and type II (primarily Activin RIIA or BMPR-II) receptors (11, 12). The bioavailability of BMP-4 is regulated by its interaction with multiple proteins and glycosaminoglycans (13-15).

References:

1. Zhang, P. *et al.* (2008) *Blood* **111**:1933.
2. Gambaro, K. *et al.* (2006) *Cell Death Differ.* **13**:1075.
3. Simic, P. and S. Vukicevic (2005) *Cytokine Growth Factor Rev.* **16**:299.
4. Sadlon, T.J. *et al.* (2004) *Stem Cells* **22**:457.
5. Frank, D.B. *et al.* (2005) *Circ. Res.* **97**:496.
6. Wozney, J. *et al.* (1988) *Science* **242**:1528.
7. Cui, Y. *et al.* (1998) *EMBO J.* **17**:4735.
8. Cui, Y. *et al.* (2001) *Genes Dev.* **15**:2797.
9. Aono, A. *et al.* (1995) *Biochem. Biophys. Res. Commun.* **210**:670.
10. Nishimatsu, S. and G.H. Thomsen (1998) *Mech. Dev.* **74**:75.
11. Chen, D. *et al.* (2004) *Growth Factors* **22**:233.
12. Lavery, K. *et al.* (2008) *J. Biol. Chem.* April 24 epub.
13. Rosen, V. (2006) *Ann. N.Y. Acad. Sci.* **1068**:19.
14. Jones, C.M. and J.C. Smith (1998) *Dev. Biol.* **194**:12.
15. Takada, T. *et al.* (2003) *J. Biol. Chem.* **278**:43229.